Every 424B that Silo Pharma, Inc. (SILO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. is registering for resale up to 1,906,392 shares of common stock held by selling shareholders. The registered shares comprise 124,000 already issued shares and shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants issued in a July 2026 private placement.
This is a resale registration; the company states it will not receive proceeds from share sales by the selling shareholders. It may receive cash only if the warrants associated with 1,782,392 of the registered shares are exercised, in which case it would receive the stated exercise prices. Following full cash exercise of those warrants, shares outstanding would be 3,035,002.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency company, with lead drug candidate SPC-15 for PTSD and anxiety, plus additional preclinical programs for fibromyalgia, Alzheimer’s disease and CNS disorders. In June 2026 it completed a 1-for-15 reverse stock split, leaving 6,666,667 authorized common shares. The company reported a 2025 net loss of $4,227,698 and held $173,462 of crypto assets at fair value as of March 31, 2026.
Silo Pharma, Inc. is registering up to 5,023,340 shares of common stock underlying Series A-1 warrants, Series A-2 warrants and placement agent warrants.
The prospectus offers common stock purchase warrants exercisable upon issuance at an exercise price of $0.60 per share; Series A-1 warrants expire five years from the Initial Exercise Date and Series A-2 warrants expire eighteen months from the Initial Exercise Date. The offering price per common stock purchase warrant is $0.60. The company states it will receive proceeds only upon cash exercise of the warrants and may receive up to approximately $3.0 million if all warrants are exercised at the stated price. The company discloses Nasdaq minimum bid-price noncompliance and a second compliance period extending to June 22, 2026, and lists operating losses and cash balances in its historical consolidated financial data.
Silo Pharma, Inc. is registering up to 820,911 shares of common stock issuable upon the exercise of certain warrants.
The Shares consist of 763,638 shares issuable upon exercise of the July 2024 Investor Warrants at $2.75 per share and 57,273 shares issuable upon exercise of the July 2024 Placement Agent Warrants at $3.4375 per share. Upon cash exercise of all Warrants the company would receive aggregate gross proceeds of approximately $2.3 million. The registration covers resale by the Selling Shareholders; the company will not receive proceeds from resale transactions.
Shares outstanding would be 17,087,504 assuming full exercise of the Warrants; Nasdaq minimum-bid noncompliance and remediation periods are disclosed.
Silo Pharma, Inc. (SILO) published a prospectus supplement describing a securities offering intended to raise net proceeds of approximately $2.15 million after placement agent fees and estimated expenses. The supplement identifies an offering price and placement agent fees that produce gross proceeds shown as $2,312,500.12 before expenses and net proceeds of about $2.15 million to be used for general corporate and working capital purposes. The document lists 2,857,143 shares in connection with Unregistered Warrants and total potential dilution from numerous outstanding options and warrants, including large tranches exercisable at prices ranging from $0.60 to $6.25 per share and specific counts such as 4,773,340 shares issuable upon exercise of May 2025 Warrants at $0.60 and 2,857,143 shares issuable upon exercise of Unregistered Warrants at $0.75. The filing emphasizes high risks, including need for additional financing, no history of profitable operations, regulatory and controlled-substance risks for psilocybin-based candidates, potential dilution, and Nasdaq listing risk.